Navigation Links
Lilly Declares Fourth-Quarter 2010 Dividend
Date:10/18/2010

INDIANAPOLIS, Oct. 18 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the fourth quarter of 2010 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in the first three quarters of 2010 and brings the total annual dividend for 2010 to $1.96 per share.

The dividend is payable December 10, 2010 to shareholders of record at the close of business on November 15, 2010.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Lilly Confirms Date and Conference Call for Third-Quarter 2010 Financial Results Announcement
2. Lilly CEO Says Regional Innovation Clusters Can Renew the Nations Economy
3. Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile
4. Lilly Celebrates 16th Consecutive Year as One of 100 Best Companies for Working Mothers
5. Lilly Recognized with World Business and Development Award for Tuberculosis Initiative
6. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
7. U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly
8. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
9. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
10. Lilly Halts Development of Semagacestat for Alzheimers Disease Based on Preliminary Results of Phase III Clinical Trials
11. The American Diabetes Association and Eli Lilly and Company Encourage African-Americans to Face the Music about Diabetes Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK ... technology, today announced Food and Drug Administration (FDA) ... defibrillator that provides heart failure patients with access ... devices also have remote monitoring with daily automatic ... the heart rate in response to physiological demands. ...
(Date:5/3/2016)... Pharmaceutical giant Johnson & Johnson has been ... says its talc-based powder products caused ovarian cancer. The ... million in compensatory damages and $50 million in punitive ... , This is the second in a ... same court awarded $72 million to the family of ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, yet ... weaken the immune system and increase inflammation, both of which raise the risk of ... congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... relationship-marketing firm, honored finalists and winners Tuesday evening, May 3, at the 2016 ... Texas. , Scott Pettigrew, Vice President and Chief Security Officer of HMS, ...
(Date:5/5/2016)... ... 2016 , ... If you don’t mind a bit of prickly therapy to ... to consider a treatment that some have called the next great tool in dermatology ... also known as skin needling, is a procedure using a device covered with tiny, ...
(Date:5/5/2016)... ... 05, 2016 , ... Pigment Laser Tattoo Removal Center is proud to be ... PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. This new ... on the market. Jeremy Miller, Tattoo Artist and former reality show contestant on ...
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD spoke ... Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was titled “Living ... conference about her unique specialization in treating Lipedema. Dr. Byrd is considered one of ...
Breaking Medicine News(10 mins):